Nkarta to Participate at Upcoming Investor Conference
03 Août 2023 - 2:02PM
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing
engineered natural killer (NK) cell therapies, today announced its
participation at an upcoming investor conference:
Canaccord Genuity
43rd Annual Growth
ConferenceAugust 10, 202312:00 p.m. ET – fireside chat
A simultaneous webcast of each event will be available on the
Investors section of Nkarta’s website, www.nkartatx.com, and a
replay will be archived on the website for approximately 90
days.
About NkartaNkarta is a clinical-stage
biotechnology company advancing the development of allogeneic,
off-the-shelf natural killer (NK) cell therapies. By combining its
cell expansion and cryopreservation platform with proprietary cell
engineering technologies and CRISPR-based genome engineering
capabilities, Nkarta is building a pipeline of future cell
therapies engineered for deep anti-tumor activity and intended for
broad access in the outpatient treatment setting. For more
information, please visit the company’s website at
www.nkartatx.com.
Nkarta Media/Investor Contact:Greg MannNkarta,
Inc.gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Graphique Historique de l'Action
De Oct 2024 à Oct 2024
Nkarta (NASDAQ:NKTX)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024